Anaveon
Basel, CH · 3 known investors
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.
Biotechin /anaveon
